Published in Trends Microbiol on October 29, 2008
Mutation of a single residue renders human tetherin resistant to HIV-1 Vpu-mediated depletion. PLoS Pathog (2009) 2.92
Understanding HIV-1 latency provides clues for the eradication of long-term reservoirs. Nat Rev Microbiol (2009) 2.47
Hexagonal assembly of a restricting TRIM5alpha protein. Proc Natl Acad Sci U S A (2010) 2.40
Ex vivo gene transfer and correction for cell-based therapies. Nat Rev Genet (2011) 2.13
Studies of endogenous retroviruses reveal a continuing evolutionary saga. Nat Rev Microbiol (2012) 1.94
The evolutionary conundrum of pathogen mimicry. Nat Rev Microbiol (2009) 1.87
Characterization of the alpha interferon-induced postentry block to HIV-1 infection in primary human macrophages and T cells. J Virol (2010) 1.69
The macrophage in HIV-1 infection: from activation to deactivation? Retrovirology (2010) 1.64
The structural biology of HIV-1: mechanistic and therapeutic insights. Nat Rev Microbiol (2012) 1.50
The utility of the new generation of humanized mice to study HIV-1 infection: transmission, prevention, pathogenesis, and treatment. Retrovirology (2011) 1.42
BCA2/Rabring7 promotes tetherin-dependent HIV-1 restriction. PLoS Pathog (2009) 1.24
BST-2 is rapidly down-regulated from the cell surface by the HIV-1 protein Vpu: evidence for a post-ER mechanism of Vpu-action. Virology (2011) 1.20
Evolutionary dynamics of the interferon-induced transmembrane gene family in vertebrates. PLoS One (2012) 1.13
Fates of retroviral core components during unrestricted and TRIM5-restricted infection. PLoS Pathog (2013) 1.13
Conformational adaptation of Asian macaque TRIMCyp directs lineage specific antiviral activity. PLoS Pathog (2010) 1.09
p62/sequestosome-1 associates with and sustains the expression of retroviral restriction factor TRIM5alpha. J Virol (2010) 1.08
Features, processing states, and heterologous protein interactions in the modulation of the retroviral nucleocapsid protein function. RNA Biol (2010) 1.08
Productive replication of Vif-chimeric HIV-1 in feline cells. J Virol (2010) 0.99
Retroelements versus APOBEC3 family members: No great escape from the magnificent seven. Front Microbiol (2012) 0.99
Restrictions to cross-species transmission of lentiviral infection gleaned from studies of FIV. Vet Immunol Immunopathol (2009) 0.93
Feline tetherin is characterized by a short N-terminal region and is counteracted by the feline immunodeficiency virus envelope glycoprotein. J Virol (2012) 0.92
Antiviral restriction factor transgenesis in the domestic cat. Nat Methods (2011) 0.92
Early potent protection against heterologous SIVsmE660 challenge following live attenuated SIV vaccination in Mauritian cynomolgus macaques. PLoS One (2011) 0.92
Molecular evolution of the primate antiviral restriction factor tetherin. PLoS One (2010) 0.92
Human ezrin-moesin-radixin proteins modulate hepatitis C virus infection. Hepatology (2013) 0.91
Proton-driven assembly of the Rous Sarcoma virus capsid protein results in the formation of icosahedral particles. J Biol Chem (2010) 0.88
Homology-based identification of capsid determinants that protect HIV1 from human TRIM5α restriction. J Biol Chem (2010) 0.84
Retroviral restriction and dependency factors in primates and carnivores. Vet Immunol Immunopathol (2011) 0.83
Restriction of HIV-1 by rhesus TRIM5α is governed by alpha helices in the Linker2 region. J Virol (2014) 0.83
Species tropism of HIV-1 modulated by viral accessory proteins. Front Microbiol (2012) 0.82
Antiretroviral therapy down-regulates innate antiviral response genes in patients with AIDS in sub-saharan Africa. J Acquir Immune Defic Syndr (2010) 0.81
Replication potentials of HIV-1/HSIV in PBMCs from northern pig-tailed macaque (Macaca leonina). Dongwuxue Yanjiu (2014) 0.81
Epitope tags beside the N-terminal cytoplasmic tail of human BST-2 alter its intracellular trafficking and HIV-1 restriction. PLoS One (2014) 0.80
Retroviral restriction factors and infectious risk in xenotransplantation. Am J Transplant (2010) 0.79
Variability in a dominant block to SIV early reverse transcription in rhesus monkey cells predicts in vivo viral replication and time to death. Virol J (2010) 0.78
Primate and feline lentiviruses in current intrinsic immunity research: the cat is back. Vet Immunol Immunopathol (2011) 0.78
Retroviral infections in sheep and goats: small ruminant lentiviruses and host interaction. Viruses (2013) 0.77
The 19S proteasome activator promotes human cytomegalovirus immediate early gene expression through proteolytic and nonproteolytic mechanisms. J Virol (2014) 0.77
A novel mosquito ubiquitin targets viral envelope protein for degradation and reduces virion production during dengue virus infection. Biochim Biophys Acta (2016) 0.77
Viral Restriction Activity of Feline BST2 Is Independent of Its N-Glycosylation and Induction of NF-κB Activation. PLoS One (2015) 0.77
Broad-spectrum antiviral agents. Front Microbiol (2015) 0.76
Candida albicans delays HIV-1 replication in macrophages. PLoS One (2013) 0.75
Involvement of endogenous retroviruses in prion diseases. Pathogens (2013) 0.75
Ultra structural characterisation of tetherin - a protein capable of preventing viral release from the plasma membrane. Viruses (2010) 0.75
Effect of type-I interferon on retroviruses. Viruses (2009) 0.75
Isolation of a human gene that inhibits HIV-1 infection and is suppressed by the viral Vif protein. Nature (2002) 21.53
The cytoplasmic body component TRIM5alpha restricts HIV-1 infection in Old World monkeys. Nature (2004) 17.56
Tetherin inhibits retrovirus release and is antagonized by HIV-1 Vpu. Nature (2008) 14.99
DNA deamination mediates innate immunity to retroviral infection. Cell (2003) 12.10
Induction of APOBEC3G ubiquitination and degradation by an HIV-1 Vif-Cul5-SCF complex. Science (2003) 10.79
The antiretroviral enzyme APOBEC3G is degraded by the proteasome in response to HIV-1 Vif. Nat Med (2003) 9.22
Interferons and viruses: an interplay between induction, signalling, antiviral responses and virus countermeasures. J Gen Virol (2008) 8.85
Cyclophilin A retrotransposition into TRIM5 explains owl monkey resistance to HIV-1. Nature (2004) 7.10
Positive selection of primate TRIM5alpha identifies a critical species-specific retroviral restriction domain. Proc Natl Acad Sci U S A (2005) 6.85
Specific recognition and accelerated uncoating of retroviral capsids by the TRIM5alpha restriction factor. Proc Natl Acad Sci U S A (2006) 6.82
Cytidine deamination of retroviral DNA by diverse APOBEC proteins. Curr Biol (2004) 6.51
Vif is crucial for human immunodeficiency virus type 1 proviral DNA synthesis in infected cells. J Virol (1993) 6.11
A second human antiretroviral factor, APOBEC3F, is suppressed by the HIV-1 and HIV-2 Vif proteins. EMBO J (2004) 5.67
Human APOBEC3F is another host factor that blocks human immunodeficiency virus type 1 replication. J Virol (2004) 5.35
Retracted Cellular APOBEC3G restricts HIV-1 infection in resting CD4+ T cells. Nature (2005) 5.28
A single amino acid change in the SPRY domain of human Trim5alpha leads to HIV-1 restriction. Curr Biol (2005) 5.24
Inhibition of hepatitis B virus replication by APOBEC3G. Science (2004) 5.15
The human and African green monkey TRIM5alpha genes encode Ref1 and Lv1 retroviral restriction factor activities. Proc Natl Acad Sci U S A (2004) 5.08
Antiviral function of APOBEC3G can be dissociated from cytidine deaminase activity. Curr Biol (2005) 4.98
APOBEC3F properties and hypermutation preferences indicate activity against HIV-1 in vivo. Curr Biol (2004) 4.89
TRIM family proteins: retroviral restriction and antiviral defence. Nat Rev Microbiol (2005) 4.89
A conserved mechanism of retrovirus restriction in mammals. Proc Natl Acad Sci U S A (2000) 4.88
Cellular inhibitors with Fv1-like activity restrict human and simian immunodeficiency virus tropism. Proc Natl Acad Sci U S A (2002) 4.66
A Trim5-cyclophilin A fusion protein found in owl monkey kidney cells can restrict HIV-1. Proc Natl Acad Sci U S A (2004) 4.06
Natural variation in Vif: differential impact on APOBEC3G/3F and a potential role in HIV-1 diversification. PLoS Pathog (2005) 3.59
Proteasome inhibitors uncouple rhesus TRIM5alpha restriction of HIV-1 reverse transcription and infection. Proc Natl Acad Sci U S A (2006) 3.43
APOBEC3F can inhibit the accumulation of HIV-1 reverse transcription products in the absence of hypermutation. Comparisons with APOBEC3G. J Biol Chem (2006) 3.03
Structure of the DNA deaminase domain of the HIV-1 restriction factor APOBEC3G. Nature (2008) 2.80
APOBEC-mediated viral restriction: not simply editing? Trends Biochem Sci (2007) 2.80
Highly attenuated vaccine strains of simian immunodeficiency virus protect against vaginal challenge: inverse relationship of degree of protection with level of attenuation. J Virol (1999) 2.69
G-->A hypermutation in protease and reverse transcriptase regions of human immunodeficiency virus type 1 residing in resting CD4+ T cells in vivo. J Virol (2005) 2.61
High-molecular-mass APOBEC3G complexes restrict Alu retrotransposition. Proc Natl Acad Sci U S A (2006) 2.54
Retroviral restriction factor TRIM5alpha is a trimer. J Virol (2005) 2.52
G-->A hypermutation of the human immunodeficiency virus type 1 genome: evidence for dCTP pool imbalance during reverse transcription. Proc Natl Acad Sci U S A (1994) 2.52
Deaminase-independent inhibition of HIV-1 reverse transcription by APOBEC3G. Nucleic Acids Res (2007) 2.49
Differential restriction of human immunodeficiency virus type 2 and simian immunodeficiency virus SIVmac by TRIM5alpha alleles. J Virol (2005) 2.43
Rhesus monkey TRIM5alpha restricts HIV-1 production through rapid degradation of viral Gag polyproteins. Nat Med (2007) 2.32
Independent genesis of chimeric TRIM5-cyclophilin proteins in two primate species. Proc Natl Acad Sci U S A (2008) 2.23
Cyclophilin A is required for TRIM5{alpha}-mediated resistance to HIV-1 in Old World monkey cells. Proc Natl Acad Sci U S A (2005) 2.21
The DNA deaminase activity of human APOBEC3G is required for Ty1, MusD, and human immunodeficiency virus type 1 restriction. J Virol (2008) 2.21
Evolution of a TRIM5-CypA splice isoform in old world monkeys. PLoS Pathog (2008) 2.20
Catalysis of cis/trans isomerization in native HIV-1 capsid by human cyclophilin A. Proc Natl Acad Sci U S A (2002) 2.19
Balancing selection and the evolution of functional polymorphism in Old World monkey TRIM5alpha. Proc Natl Acad Sci U S A (2006) 2.16
Independent evolution of an antiviral TRIMCyp in rhesus macaques. Proc Natl Acad Sci U S A (2008) 2.15
TRIMCyp expression in Old World primates Macaca nemestrina and Macaca fascicularis. Proc Natl Acad Sci U S A (2008) 2.09
The interferon response inhibits HIV particle production by induction of TRIM22. PLoS Pathog (2008) 2.06
TRIM E3 ligases interfere with early and late stages of the retroviral life cycle. PLoS Pathog (2008) 2.05
Enzymatically active APOBEC3G is required for efficient inhibition of human immunodeficiency virus type 1. J Virol (2007) 2.03
Antiretroviral potential of human tripartite motif-5 and related proteins. Virology (2006) 1.94
Visualization of a proteasome-independent intermediate during restriction of HIV-1 by rhesus TRIM5alpha. J Cell Biol (2008) 1.88
Generation of simian-tropic HIV-1 by restriction factor evasion. Science (2006) 1.84
Cytidine deamination induced HIV-1 drug resistance. Proc Natl Acad Sci U S A (2008) 1.83
Comparative requirements for the restriction of retrovirus infection by TRIM5alpha and TRIMCyp. Virology (2007) 1.75
Selective inhibition of Alu retrotransposition by APOBEC3G. Gene (2006) 1.75
A novel fusion gene, TRIM5-Cyclophilin A in the pig-tailed macaque determines its susceptibility to HIV-1 infection. AIDS (2007) 1.71
Newly synthesized APOBEC3G is incorporated into HIV virions, inhibited by HIV RNA, and subsequently activated by RNase H. PLoS Pathog (2007) 1.70
Cyclophilin A renders human immunodeficiency virus type 1 sensitive to Old World monkey but not human TRIM5 alpha antiviral activity. J Virol (2006) 1.69
Trim-cyclophilin A fusion proteins can restrict human immunodeficiency virus type 1 infection at two distinct phases in the viral life cycle. J Virol (2006) 1.66
Generation of HIV-1 derivatives that productively infect macaque monkey lymphoid cells. Proc Natl Acad Sci U S A (2006) 1.63
Mechanisms of protection induced by attenuated simian immunodeficiency virus. I. Protection cannot be transferred with immune serum. J Gen Virol (1997) 1.62
An active TRIM5 protein in rabbits indicates a common antiviral ancestor for mammalian TRIM5 proteins. J Virol (2007) 1.54
Ubiquitination of E3 ubiquitin ligase TRIM5 alpha and its potential role. FEBS J (2008) 1.53
Evolution of a cytoplasmic tripartite motif (TRIM) protein in cows that restricts retroviral infection. Proc Natl Acad Sci U S A (2006) 1.53
Dual inhibitory effects of APOBEC family proteins on retrotransposition of mammalian endogenous retroviruses. Nucleic Acids Res (2006) 1.53
Alpha interferon enhances TRIM5alpha-mediated antiviral activities in human and rhesus monkey cells. J Virol (2007) 1.49
The effect of Trim5 polymorphisms on the clinical course of HIV-1 infection. PLoS Pathog (2008) 1.41
Turning up the volume on mutational pressure: is more of a good thing always better? (A case study of HIV-1 Vif and APOBEC3). Retrovirology (2008) 1.36
Isolation of an active Lv1 gene from cattle indicates that tripartite motif protein-mediated innate immunity to retroviral infection is widespread among mammals. J Virol (2006) 1.35
Rhesus macaque TRIM5 alleles have divergent antiretroviral specificities. J Virol (2008) 1.29
Retroviral restriction factors Fv1 and TRIM5alpha act independently and can compete for incoming virus before reverse transcription. J Virol (2006) 1.25
Resistance to superinfection by a vigorously replicating, uncloned stock of simian immunodeficiency virus (SIVmac251) stimulates replication of a live attenuated virus vaccine (SIVmacC8). J Gen Virol (2008) 1.11
No effect of endogenous TRIM5alpha on HIV-1 production. Nat Med (2008) 1.08
CD8+ lymphocytes do not mediate protection against acute superinfection 20 days after vaccination with a live attenuated simian immunodeficiency virus. J Virol (2005) 1.05
APOBEC3G restricts early HIV-1 replication in the cytoplasm of target cells. Virology (2008) 1.04
APOBEC3G versus reverse transcriptase in the generation of HIV-1 drug-resistance mutations. AIDS (2004) 1.02
Fusion of cyclophilin A to Fv1 enables cyclosporine-sensitive restriction of human and feline immunodeficiency viruses. J Virol (2007) 0.97
Estimating the relative contribution of dNTP pool imbalance and APOBEC3G/3F editing to HIV evolution in vivo. J Comput Biol (2007) 0.95
AIDS research. Review of vaccine failure prompts a return to basics. Science (2008) 0.92
The human and African green monkey TRIM5alpha genes encode Ref1 and Lv1 retroviral restriction factor activities. Proc Natl Acad Sci U S A (2004) 5.08
Restriction of multiple divergent retroviruses by Lv1 and Ref1. EMBO J (2003) 4.19
Mutation of a single residue renders human tetherin resistant to HIV-1 Vpu-mediated depletion. PLoS Pathog (2009) 2.92
Disease-associated XMRV sequences are consistent with laboratory contamination. Retrovirology (2010) 2.90
HIV-1 capsid-cyclophilin interactions determine nuclear import pathway, integration targeting and replication efficiency. PLoS Pathog (2011) 2.68
Differential restriction of human immunodeficiency virus type 2 and simian immunodeficiency virus SIVmac by TRIM5alpha alleles. J Virol (2005) 2.43
Antibodies mediate intracellular immunity through tripartite motif-containing 21 (TRIM21). Proc Natl Acad Sci U S A (2010) 2.36
Simian immunodeficiency virus envelope glycoprotein counteracts tetherin/BST-2/CD317 by intracellular sequestration. Proc Natl Acad Sci U S A (2009) 2.21
Independent evolution of an antiviral TRIMCyp in rhesus macaques. Proc Natl Acad Sci U S A (2008) 2.15
HIV integration targeting: a pathway involving Transportin-3 and the nuclear pore protein RanBP2. PLoS Pathog (2011) 2.00
Characterization of murine leukemia virus restriction in mammals. J Virol (2003) 1.97
The RING-CH ligase K5 antagonizes restriction of KSHV and HIV-1 particle release by mediating ubiquitin-dependent endosomal degradation of tetherin. PLoS Pathog (2010) 1.94
As(2)O(3) enhances retroviral reverse transcription and counteracts Ref1 antiviral activity. J Virol (2003) 1.94
Cyclophilin A renders human immunodeficiency virus type 1 sensitive to Old World monkey but not human TRIM5 alpha antiviral activity. J Virol (2006) 1.69
CPSF6 defines a conserved capsid interface that modulates HIV-1 replication. PLoS Pathog (2012) 1.64
Influence of gag on human immunodeficiency virus type 1 species-specific tropism. J Virol (2004) 1.57
An active TRIM5 protein in rabbits indicates a common antiviral ancestor for mammalian TRIM5 proteins. J Virol (2007) 1.54
Active site remodeling switches HIV specificity of antiretroviral TRIMCyp. Nat Struct Mol Biol (2009) 1.53
HIV-1 uses dynamic capsid pores to import nucleotides and fuel encapsidated DNA synthesis. Nature (2016) 1.39
Gag determinants of fitness and drug susceptibility in protease inhibitor-resistant human immunodeficiency virus type 1. J Virol (2009) 1.37
SAMHD1-dependent retroviral control and escape in mice. EMBO J (2013) 1.36
Isolation of an active Lv1 gene from cattle indicates that tripartite motif protein-mediated innate immunity to retroviral infection is widespread among mammals. J Virol (2006) 1.35
HIV-1 infection of macrophages is dependent on evasion of innate immune cellular activation. AIDS (2009) 1.34
Full-length HIV-1 Gag determines protease inhibitor susceptibility within in vitro assays. AIDS (2010) 1.29
Rhesus macaque TRIM5 alleles have divergent antiretroviral specificities. J Virol (2008) 1.29
Cyclophilin A levels dictate infection efficiency of human immunodeficiency virus type 1 capsid escape mutants A92E and G94D. J Virol (2008) 1.27
Retroviral restriction factors Fv1 and TRIM5alpha act independently and can compete for incoming virus before reverse transcription. J Virol (2006) 1.25
Phylogenetic analysis of murine leukemia virus sequences from longitudinally sampled chronic fatigue syndrome patients suggests PCR contamination rather than viral evolution. J Virol (2011) 1.23
Analysis of XMRV integration sites from human prostate cancer tissues suggests PCR contamination rather than genuine human infection. Retrovirology (2011) 1.20
HIV-1 Group P is unable to antagonize human tetherin by Vpu, Env or Nef. Retrovirology (2011) 1.18
No evidence of XMRV in prostate cancer cohorts in the Midwestern United States. Retrovirology (2011) 1.18
Conformational adaptation of Asian macaque TRIMCyp directs lineage specific antiviral activity. PLoS Pathog (2010) 1.09
Cyclosporine increases human immunodeficiency virus type 1 vector transduction of primary mouse cells. J Virol (2006) 1.09
TRIM22 inhibits influenza A virus infection by targeting the viral nucleoprotein for degradation. J Virol (2013) 1.08
Truncation of TRIM5 in the Feliformia explains the absence of retroviral restriction in cells of the domestic cat. J Virol (2009) 1.08
Feline tetherin efficiently restricts release of feline immunodeficiency virus but not spreading of infection. J Virol (2011) 1.04
No evidence of XMRV or related retroviruses in a London HIV-1-positive patient cohort. PLoS One (2011) 1.04
HIV-1 capsid undergoes coupled binding and isomerization by the nuclear pore protein NUP358. Retrovirology (2013) 1.01
Fusion of cyclophilin A to Fv1 enables cyclosporine-sensitive restriction of human and feline immunodeficiency viruses. J Virol (2007) 0.97
Impact of the N348I mutation in HIV-1 reverse transcriptase on nonnucleoside reverse transcriptase inhibitor resistance in non-subtype B HIV-1. Antimicrob Agents Chemother (2011) 0.96
Tetherin restricts herpes simplex virus 1 and is antagonized by glycoprotein M. J Virol (2013) 0.95
Early antigen presentation of protective HIV-1 KF11Gag and KK10Gag epitopes from incoming viral particles facilitates rapid recognition of infected cells by specific CD8+ T cells. J Virol (2012) 0.93
Adherent human alveolar macrophages exhibit a transient pro-inflammatory profile that confounds responses to innate immune stimulation. PLoS One (2012) 0.93
Analysis of the human immunodeficiency virus type 1 M group Vpu domains involved in antagonizing tetherin. J Gen Virol (2011) 0.92
A tail of Tetherin: how pandemic HIV-1 conquered the world. Cell Host Microbe (2009) 0.91
Identification of an arsenic-sensitive block to primate lentiviral infection of human dendritic cells. J Virol (2007) 0.87
Hare TRIM5α restricts divergent retroviruses and exhibits significant sequence variation from closely related lagomorpha TRIM5 genes. J Virol (2010) 0.87
Cellular restriction of retrovirus particle-mediated mRNA transfer. J Virol (2008) 0.85
HLA-specific intracellular epitope processing shapes an immunodominance pattern for HLA-B*57 that is distinct from HLA-B*58:01. J Virol (2013) 0.85
Inhibition of retroviral replication by members of the TRIM protein family. Curr Top Microbiol Immunol (2013) 0.84
Diversity of TRIM5α and TRIMCyp sequences in cynomolgus macaques from different geographical origins. Immunogenetics (2011) 0.83
Endoplasmic reticulum degradation-enhancing α-mannosidase-like protein 1 targets misfolded HLA-B27 dimers for endoplasmic reticulum-associated degradation. Arthritis Rheumatol (2014) 0.81
Vpx complementation of 'non-macrophage tropic' R5 viruses reveals robust entry of infectious HIV-1 cores into macrophages. Retrovirology (2014) 0.81
Upregulation of TRIM5α gene expression after live-attenuated simian immunodeficiency virus vaccination in Mauritian cynomolgus macaques, but TRIM5α genotype has no impact on virus acquisition or vaccination outcome. J Gen Virol (2012) 0.81
Diverse HIV viruses are targeted by a conformationally dynamic antiviral. Nat Struct Mol Biol (2012) 0.81
Porcine endogenous retroviruses PERV A and A/C recombinant are insensitive to a range of divergent mammalian TRIM5alpha proteins including human TRIM5alpha. J Gen Virol (2009) 0.81
Lentiviral gene therapy against human immunodeficiency virus type 1, using a novel human TRIM21-cyclophilin A restriction factor. Hum Gene Ther (2012) 0.79
Ultra structural characterisation of tetherin - a protein capable of preventing viral release from the plasma membrane. Viruses (2010) 0.75